A PIVKA-Ⅱ detection kit and preparation method thereof
By constructing an anti-SA antibody-SA-biotin amplification system and optimizing the diameter of magnetic beads and the antibody ratio, the problems of low sensitivity and limited linear range of the PIVKA-II detection kit were solved, achieving high sensitivity and wide linear range for PIVKA-II detection.
Patent Information
- Application Number
- CN202211175392.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-09-26
- Publication Date
- 2024-11-12
- Estimated Expiration
- 2042-09-26
AI Technical Summary
Existing PIVKA-II detection kits have low sensitivity and limited linear range, which limits the clinical detection of serum PIVKA-II.
Reagents M and R were prepared using dilution buffer I and dilution buffer II. Reagent M consisted of magnetic beads conjugated with biotinylated mouse anti-human PIVKA-II monoclonal antibody, and reagent R consisted of rabbit anti-human PIVKA-II polyclonal antibody labeled with alkaline phosphatase. By constructing an anti-SA antibody-SA-biotin amplification system, the diameter of the magnetic beads and the antibody ratio were optimized to improve the detection sensitivity and linear range.
The detection sensitivity of PIVKA-II was improved and the linear range was expanded. The detection limit of PIVKA-II reached 5.00 mAU/mL, and the detection range reached 5.00~35000.00 mAU/mL, which significantly improved the detection effect.
Smart Images

Figure BDA0003864973240000061 
Figure BDA0003864973240000071 
Figure BDA0003864973240000072
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of immunoassay, and specifically relates to a PIVKA-II detection kit and a preparation method thereof. Background Art
[0002] PIVKA-II (Protein Induced by Vitamin K Absence or Antagonist-II), also known as des-gamma carboxy prothrombin (DCP), is a protein induced by vitamin K deficiency or antagonist-II and can appear in the serum of patients with vitamin K deficiency or hepatocellular carcinoma (HCC).
[0003] At present, PIVKA-II has been listed as an extremely important indicator for liver cancer detection both at home and abroad. PIVKA-II is more specific for the diagnosis of hepatocellular carcinoma than AFP (alpha-fetoprotein). Other liver diseases rarely cause PIVKA-II to increase. The serum half-life of PIVKA-II (40-72 hours) is much shorter than the half-life of AFP (5-7 days), which can better monitor the disease. There is no positive or negative correlation between PIVKA-II and AFP serum levels in hepatocellular carcinoma, so it can complement AFP to improve the sensitivity and specificity of HCC diagnosis.
[0004] A variety of detection methods have been introduced into the clinical examination of PIVKA-II, including radioimmunoassay (RIA), enzyme-linked immunosorbent assay (ELISA), traditional enzyme immunoassay (EIA) and CLEIA detection. However, the above analytical methods based on the detection of serum PIVKA-II have problems such as insufficient sensitivity and accuracy, large and complex equipment, expensive supporting reagents, or high workload and long-term nature, which inevitably bring many limitations to the clinical detection of serum PIVKA-II. Summary of the invention
[0005] In view of the problem that the existing PIVKA-Ⅱ detection kit has low sensitivity, the object of the present invention is to provide a PIVKA-Ⅱ detection kit, which not only has higher PIVKA-Ⅱ detection sensitivity, but also has a wider linear range.
[0006] In order to achieve the above object, the technical solution of the present invention is as follows:
[0007] A PIVKA-Ⅱ detection kit comprises a reagent M and a reagent R, wherein the reagent M comprises a diluent I and magnetic beads coupled with a biotinylated mouse anti-human PIVKA-Ⅱ monoclonal antibody, and the reagent R comprises a diluent II and an alkaline phosphatase-labeled rabbit anti-human PIVKA-Ⅱ polyclonal antibody.
[0008] Among them, the structure of the magnetic bead particles coupled with biotinylated mouse anti-human PIVKA-Ⅱ monoclonal antibodies is specifically as follows: the surface of the magnetic bead particles is first coated with anti-SA antibodies, then connected to SA, and then coupled with biotinylated mouse anti-human PIVKA-Ⅱ monoclonal antibodies; the diameter of the magnetic bead particles is 0.8μm to 3μm.
[0009] Furthermore, in the above technical solution, the mass ratio of magnetic beads to anti-SA antibody, SA, and biotinylated mouse anti-human PIVKA-Ⅱ monoclonal antibody is 0.3:(0.2-0.5):(0.01-0.05):(0.2-0.5).
[0010] Optimally, the mass ratio of magnetic beads to anti-SA antibody, SA, and biotinylated mouse anti-human PIVKA-Ⅱ monoclonal antibody is 0.3:0.25:0.02:0.5.
[0011] Furthermore, in the above technical solution, the mass ratio of alkaline phosphatase to rabbit anti-human PIVKA-Ⅱ polyclonal antibody is (0.25-0.5):(0.5-1), and the mass ratio of magnetic beads to alkaline phosphatase is 0.3:(0.25-0.5).
[0012] Optimally, the activity of alkaline phosphatase is >2000 glycine U / mg protein, and the mass ratio of alkaline phosphatase to rabbit anti-human PIVKA-II polyclonal antibody is 0.5:0.5.
[0013] Furthermore, in the above technical solution, the diluent I comprises: 0.03% to 0.1% Proclin 300, 0.02 to 0.05 mol / L buffer, 0.2% to 2% surfactant, 0.1% to 0.5% protein, and pH 7.0 to 8.0.
[0014] In diluent I, the buffer can be one of PB buffer, MOPS buffer, TES buffer, HEPES buffer and DIPSO buffer. Among them, MOPSO buffer belongs to Good's buffer, and its Chinese name is 3-(N-morpholinyl)-2-hydroxypropanesulfonic acid, a new zwitterionic buffer for biological research, with a buffering capacity between pH 6.2 and 7.6, and is one of the most commonly used buffers in low-temperature biochemical work; TES is N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid, and the buffering capacity of this buffer system is between pH 6.8 and 8.2; HEPES is 4-hydroxyethylpiperazineethanesulfonic acid, a hydrogen ion buffer, and the buffering capacity of this buffer system is between pH 6.8 and 8.2; DIPSO is 3-[N,N-di(hydroxyethyl)amino]-2-hydroxypropanesulfonic acid, and the buffering capacity of this buffer system is between pH 7.0 and 8.2. These buffer systems can maintain a constant pH value of around 7.4 for a long period of time.
[0015] In diluent I, the surfactant may be one of Brij-35 (polyoxyethylene lauryl ether), S9 (Tetronic 1307), Emulgen A90 (polyoxyethylene distyrenated phenyl ether) and PEG-20000.
[0016] In diluent I, the protein is specifically a protein substance that is unrelated to the antigen-antibody reaction in reagent M, such as BSA and bovine gamma globulin, which can play a blocking role, reduce nonspecific adsorption, and reduce the zero-point signal value, thereby increasing the signal-to-noise ratio and improving sensitivity.
[0017] Optimally, the composition of diluent I is as follows: 0.05% Proclin 300, 0.02 mol / L MOPS buffer, 2% PEG-20000, 0.1% bovine gamma globulin, and pH 7.4.
[0018] Furthermore, in the above technical solution, diluent II includes: 0.9% sodium chloride, 1 mM magnesium chloride hexahydrate, 0.1 mM anhydrous zinc chloride, 0.1% bovine serum albumin, 0.05% Proclin 300, and 0.02M Tris-HCl buffer with a pH of 7.4 to 8.0.
[0019] The present invention further provides a method for preparing the above-mentioned PIVKA-Ⅱ detection kit, comprising the following steps:
[0020] S1. Activate magnetic beads with a diameter of 0.8 μm to 3 μm with an activator, add anti-SA antibody to the activated magnetic beads for coupling reaction, then add SA for reaction, finally add biotinylated mouse anti-human PIVKA-Ⅱ monoclonal antibody for reaction, add glycine solution to quench the reaction, wash and resuspend after the reaction is completed to obtain magnetic beads coupled with biotinylated mouse anti-human PIVKA-Ⅱ monoclonal antibody, and dilute with diluent I to obtain reagent M;
[0021] S2. Take alkaline phosphatase, rabbit anti-human PIVKA-Ⅱ polyclonal antibody and glutaraldehyde for cross-linking reaction. After the cross-linking reaction is completed, add ethanolamine. After the reaction is completed, dialyze to obtain alkaline phosphatase-labeled rabbit anti-human PIVKA-Ⅱ polyclonal antibody, and dilute it with diluent Ⅱ to obtain reagent R.
[0022] Preferably, the method for activating the magnetic beads in step S1 is as follows: after repeatedly washing and resuspending the magnetic beads with PBS buffer, an activator EDC is added to react.
[0023] Preferably, the cross-linking reaction in step S2 is specifically as follows: alkaline phosphatase and rabbit anti-human PIVKA-Ⅱ polyclonal antibody are dissolved in physiological saline in proportion, glutaraldehyde is added and reacted at room temperature in the dark. In this cross-linking reaction, glutaraldehyde as a cross-linking agent has two active aldehyde groups, which can be combined with the amino groups on the enzyme molecule and the antibody molecule respectively, thereby achieving the combination of the enzyme and the antibody.
[0024] When the PIVKA-Ⅱ detection kit provided by the present invention is used for quantitative analysis of PIVKA-Ⅱ, the specific principle is as follows: after incubation of PIVKA-Ⅱ in the sample to be tested with magnetic beads coated with anti-SA antibody-SA-biotinylated anti-PIVKA-Ⅱ monoclonal antibody and anti-PIVKA-Ⅱ polyclonal antibody labeled with alkaline phosphatase, PIVKA-Ⅱ and magnetic beads coated with anti-SA antibody-SA-biotinylated anti-PIVKA-Ⅱ monoclonal antibody bind, and at the same time, another site of PIVKA-Ⅱ binds to the anti-PIVKA-Ⅱ polyclonal antibody-alkaline phosphatase marker to form complex; after the reaction is completed, the magnetic field adsorbs the magnetic beads and washes away the unbound substances; the added luminescent substrate is decomposed by alkaline phosphatase, the phosphate group is hydrolyzed and a phosphate group is removed to generate an unstable intermediate, which is split into a molecule of adamantane ketone and a molecule of methyl m-oxybenzoate anion in an excited state through intramolecular electron transfer, and generates chemiluminescence when it returns to the ground state, and then the number of photons in the reaction is measured by a photomultiplier tube, and the number of photons generated is proportional to the concentration of PIVKA-Ⅱ in the sample; according to the calibration curve, the content of PIVKA-Ⅱ in the sample can be calculated.
[0025] The beneficial effects of the present invention are:
[0026] 1) The present invention constructs an anti-SA antibody-SA-biotin amplification system by coating anti-SA antibodies on magnetic beads, introducing SA to solidify it, and then combining the solidified SA with the biotinylated antibody, thereby greatly extending the spatial arm length and improving the steric hindrance effect;
[0027] 2) On the basis of the above method system, the sensitivity of PIVKA-Ⅱ detection was improved and the linear range of PIVKA-Ⅱ detection was expanded by further coordinating the mass ratio of anti-SA antibody, SA, biotinylated mouse monoclonal antibody, alkaline phosphatase and rabbit polyclonal antibody;
[0028] 3) Based on the anti-SA antibody-SA-biotin amplification system constructed in the present invention, the diameter of the magnetic bead particles is further reduced, thereby optimizing the minimum detection limit of the kit; moreover, the smaller diameter provides a larger antibody binding area at the same mass concentration, which helps to broaden the linear range of immunoassay and avoids the problem that the increase in the diameter of the magnetic bead particles will lead to a decrease in the total surface area of the solid phase carrier, thereby causing a decrease in the amount of antibody bound to the carrier. DETAILED DESCRIPTION
[0029] In order to make the purpose, technical scheme and advantages of the present invention more clear, the present invention is further described in detail below in combination with embodiments and experimental data. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not intended to limit the present invention.
[0030] Throughout the specification, unless otherwise specifically stated, the terms used herein should be understood as meanings commonly used in the art. Therefore, unless otherwise defined, all technical and scientific terms used herein have the same meanings as those generally understood by those skilled in the art to which the present invention belongs. In the event of a conflict, the present specification takes precedence.
[0031] In the following examples, unless otherwise specified, all methods are conventional methods; the reagents and materials described, unless otherwise specified, can be obtained from commercial sources.
[0032] Example 1
[0033] The detection kit provided in this embodiment is specifically:
[0034] In reagent M: the diameter of the magnetic beads is 1.5 μm, and the mass ratio of the magnetic beads to the anti-SA antibody, SA, and biotinylated mouse anti-human PIVKA-Ⅱ monoclonal antibody is 0.3:0.25:0.02:0.5; the diluent I is specifically: 0.05% Proclin300, 0.02 mol / L DIPSO buffer, 2% PEG-20000, 0.1% bovine gamma globulin, pH 7.4.
[0035] In reagent R: the activity of alkaline phosphatase is greater than 2000 glycine μ / mg protein, the mass ratio of alkaline phosphatase to rabbit anti-human PIVKA-Ⅱ polyclonal antibody is 0.5:0.5; diluent II is specifically 0.9% sodium chloride, 1mM magnesium chloride hexahydrate, 0.1mM anhydrous zinc chloride, 0.1% bovine serum albumin, 0.05% Proclin300, and 0.02M Tris-HCl buffer with a pH of 7.4.
[0036] Moreover, the mass ratio of magnetic beads to alkaline phosphatase was 0.3:0.5.
[0037] The preparation process of the above detection kit is specifically as follows:
[0038] (1) Preparation of reagent M:
[0039] ① Take 100 μL of 3 mg / mL magnetic beads into a 2 mL EP tube, place it on a magnetic separator for 4 min, and discard the supernatant; add 150 μL of 0.1 M PBS buffer, blow evenly, place it on a magnetic separator for 4 min, discard the supernatant, and repeat washing 3 times; after washing, add 90 μL of 0.1 mol / L PBS buffer to resuspend; add 100 μL of 10 mg / mL EDC activator, blow evenly, place it on an oscillator, react for 30 min, place it on a magnetic separator for 4 min, and discard the supernatant.
[0040] ② Add anti-SA antibody to the activated magnetic microparticles in proportion and carry out coupling reaction at room temperature; after the magnetic microparticles are coupled with anti-SA antibody, add SA in proportion and react at room temperature; add biotinylated mouse anti-human PIVKA-Ⅱ monoclonal antibody to the obtained SA magnetic microparticles in proportion for coupling, specifically: first dilute with 0.1 mol / L PBS buffer to a total volume of 500 μL, shake at room temperature overnight, place on a magnetic separator for separation for 4 minutes, discard the supernatant, and wash twice with PBS buffer.
[0041] ③ After the coupling is completed, add glycine solution quenching solution (1 mol / L, pH 8.0) and mix at room temperature for 30 minutes, then wash twice with 0.01M PBS buffer containing 0.1% Tween 20 and 0.1% BSA. After magnetic separation and removal of the supernatant, wash with 0.1% BSA PBS buffer, resuspend to 1 mL, and place at 2-8°C for use.
[0042] ④ After diluting 50 times with diluent Ⅰ, it can be used directly as reagent M.
[0043] (2) Preparation of reagent R:
[0044] ① Alkaline phosphatase and rabbit anti-human PIVKA-Ⅱ polyclonal antibody were dissolved in 0.5 mL of normal saline according to the proportion, 0.05 mL of 1% glutaraldehyde was added, and the mixture was reacted at room temperature at 120 rpm for 15 min, and then protected from light for 4 h; 0.1 mL of 1 M ethanolamine was then added and the mixture was reacted at room temperature at 120 rpm for 2 h. The reaction solution was dialyzed in PBS buffer at 4°C overnight, and stored at -20°C with glycerol containing 1% BSA and an equal volume to the dialyzed mixture.
[0045] ② After diluting 1000 times with diluent Ⅱ, it can be used directly as reagent R.
[0046] Example 2
[0047] Different from Example 1, the diameter of the magnetic beads in this example is 3 μm.
[0048] Example 3
[0049] Different from Example 2, the mass ratio of magnetic beads to anti-SA antibody, SA, and biotinylated mouse anti-human PIVKA-Ⅱ monoclonal antibody is 0.3:0.5:0.02:0.5.
[0050] Example 4
[0051] Different from Example 2, the mass ratio of magnetic beads to anti-SA antibody, SA, and biotinylated mouse anti-human PIVKA-Ⅱ monoclonal antibody is 0.3:0.25:0.01:0.5.
[0052] Example 5
[0053] Different from Example 2, the mass ratio of magnetic beads to anti-SA antibody, SA, and biotinylated mouse anti-human PIVKA-Ⅱ monoclonal antibody is 0.3:0.25:0.05:0.5.
[0054] Example 6
[0055] Different from Example 2, the mass ratio of magnetic beads to anti-SA antibody, SA, and biotinylated mouse anti-human PIVKA-Ⅱ monoclonal antibody is 0.3:0.25:0.02:0.25.
[0056] Example 7
[0057] Different from Example 2, the mass ratio of alkaline phosphatase to rabbit anti-human PIVKA-Ⅱ polyclonal antibody is 0.5:1.0.
[0058] Example 8
[0059] Unlike Example 2, the activity of alkaline phosphatase was >1800 glycine u / mg protein but less than 2000.
[0060] Example 9
[0061] Different from Example 1, the diameter of the magnetic beads in this example is 0.8 μm.
[0062] Example 10
[0063] Different from Example 2, the mass ratio of alkaline phosphatase to rabbit anti-human PIVKA-Ⅱ polyclonal antibody is 0.25:0.5, and the mass ratio of magnetic beads to alkaline phosphatase is 0.3:0.25.
[0064] Comparative Example 1
[0065] Different from Example 2, the mass ratio of magnetic beads to anti-SA antibody, SA, and biotinylated mouse anti-human PIVKA-Ⅱ monoclonal antibody is 0.3:0.1:0.02:0.5.
[0066] Comparative Example 2
[0067] Different from Example 2, the mass ratio of magnetic beads to anti-SA antibody, SA, and biotinylated mouse anti-human PIVKA-Ⅱ monoclonal antibody is 0.3:0.25:0.005:0.5.
[0068] Comparative Example 3
[0069] Different from Example 2, the mass ratio of magnetic beads to anti-SA antibody, SA, and biotinylated mouse anti-human PIVKA-Ⅱ monoclonal antibody is 0.3:0.25:0.02:0.1.
[0070] Comparative Example 4
[0071] Different from Example 2, the alkaline phosphatase activity was >1600 glycine U / mg protein but less than 1800.
[0072] The sensitivity test was performed using the detection kits prepared in the above embodiments and comparative examples, and the optimized detection parameters were: 50 μL reagent M, 50 μL reagent R, 10 μL serum sample (the concentration was detected using Roche PIVKA-Ⅱ electrochemiluminescence kit, which is authoritative in the industry), incubated at 37°C for 15 min, and read after washing and magnetic separation.
[0073] The results analysis specifically includes the following aspects:
[0074] 1) The effect of magnetic bead particle diameter on sensitivity.
[0075] The test results of Examples 1, 2, and 9 are shown in the following table:
[0076]
[0077]
[0078] It can be seen from the above table that when the diameter of the magnetic bead particles is 0.8μm, the signal-to-noise ratio of 5.34 / 0 is 1.73, the signal-to-noise ratio of 35942 / 19668 is 1.73, and the linear correlation coefficient is r=0.9994; when the diameter of the magnetic bead particles is 1.5μm, the photon value of the measured sample increases, the signal-to-noise ratio of 5.34 / 0 is 1.50, the signal-to-noise ratio of 35942 / 19668 is 1.74, and the linear correlation coefficient is r=0.9999; when the diameter of the magnetic bead particles is 3μm, the photon value of the measured sample increases, the signal-to-noise ratio of 5.34 / 0 is 3.46, the signal-to-noise ratio of 35942 / 19668 is 1.90, and the linear correlation coefficient is r=0.9993, indicating that magnetic bead particles with a diameter of 1.5 to 3μm can further improve the detection sensitivity of PIVKA-Ⅱ.
[0079] 2) The influence of the mass ratio of anti-SA antibody, SA, and biotinylated mouse anti-human PIVKA-Ⅱ monoclonal antibody on sensitivity is shown in the following table:
[0080]
[0081]
[0082] From the data of Comparative Example 1 and Examples 2 and 3, it can be seen that as the amount of anti-SA antibody used increases, the photon value signal and the 5.34 / 0 signal-to-noise ratio first increase and then decrease, among which Example 2 is the best. The above results show that appropriately increasing the amount of anti-SA antibody can increase the photon value signal and the signal-to-noise ratio of low-concentration samples to zero, thereby achieving the purpose of improving sensitivity; when the amount of anti-SA antibody is too small, the sensitivity is insufficient; when the amount of anti-SA antibody is too large, the photon value signal will decrease and the background will increase, resulting in a decrease in the 0.54 / 0 signal-to-noise ratio.
[0083] From the data of comparative example 2 and examples 4, 2 and 5, it can be seen that with the increase of SA dosage, the photon value signal and 5.34 / 0 signal-to-noise ratio first increase and then decrease, among which example 2 is the best.
[0084] From the data of Comparative Example 3 and Examples 6 and 2, it can be seen that with the increase in the dosage of biotinylated mouse anti-human PIVKA-Ⅱ monoclonal antibody, the photon value signal and 5.34 / 0 signal-to-noise gradually increased, among which Example 2 was the best.
[0085] In summary, when the mass ratio of anti-SA antibody, SA, and biotinylated mouse anti-human PIVKA-Ⅱ monoclonal antibody in Example 2 was 0.25:0.02:0.5, the photon value was the highest, the sensitivity was the best, and the linearity met the requirements.
[0086] 3) The effects of different active alkaline phosphatases and their ratios to rabbit anti-human PIVKA-Ⅱ polyclonal antibodies on sensitivity. The test results are shown in the following table:
[0087]
[0088]
[0089] From the data of Example 2 and Example 10, it can be seen that after the relative amount of alkaline phosphatase increases, the photon value signal and the 5.34 / 0 signal-to-noise ratio are both increased, indicating that increasing the amount of alkaline phosphatase can improve the detection sensitivity of PIVKA-Ⅱ. From the data of Example 7 and Example 2, it can be seen that after increasing the amount of rabbit anti-human PIVKA-Ⅱ polyclonal antibody, the photon value signal and the 5.34 / 0 signal-to-noise ratio are not significantly improved, and the 35942 / 19668 signal-to-noise ratio is reduced, indicating that too high an antibody concentration will also have an adverse effect.
[0090] From the data of Comparative Example 4, Example 8 and Example 2, it can be seen that as the activity of alkaline phosphatase increases, the photon value signal and the 5.34 / 0 signal-to-noise ratio, 35942 / 19668 signal-to-noise ratio, and the correlation coefficient all increase, indicating that high-activity alkaline phosphatase can improve detection sensitivity.
[0091] 4) Comparison between the detection kit of the present invention and the Roche PIVKA-Ⅱ electrochemiluminescence kit.
[0092] The detection kit of the present invention and the Roche PIVKA-Ⅱ electrochemiluminescence kit were used to simultaneously detect samples in the range of 5 to 35000 mAU / mL, and the detection results are shown in the following table:
[0093]
[0094]
[0095] From the above table, it can be seen that when detecting 42 samples in the range of 5 to 35000 mAU / mL, the correlation between the kit of Example 2 and the Roche electrochemiluminescence PIVIKA-Ⅱ kit is r>0.9900, that is, the detection kit of the present invention can achieve the same detection range as the Roche kit and has a good correlation with the Roche kit.
[0096] In summary, the PIVIKA-Ⅱ kit provided by the present invention can significantly improve the detection sensitivity of PIVKA-Ⅱ while expanding the linear range of PIVKA-Ⅱ detection by constructing an anti-SA antibody-SA-biotin amplification system, and improving parameters such as the diameter of magnetic bead particles, diluent I, the ratio of anti-SA antibody, SA, and biotinylated mouse anti-human PIVKA-Ⅱ monoclonal antibody, and the ratio of high-activity alkaline phosphatase to rabbit anti-human PIVKA-Ⅱ polyclonal antibody. The detection limit of PIVKA-Ⅱ can reach 5.00mAU / mL, and the detection range can reach 5.00~35000.00mAU / mL.
[0097] Finally, it should be noted that the terms "comprises," "includes," or any other variations thereof are intended to cover non-exclusive inclusion, such that a process, method, article, or apparatus that includes a series of elements includes not only those elements, but also other elements not explicitly listed, or also includes elements that are inherent to such process, method, article, or apparatus.
[0098] The above description is a preferred embodiment of the present invention, which cannot be used to limit the scope of rights of the present invention. It should be pointed out that for ordinary technicians in this technical field, any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the protection scope of the present invention.
Claims
1. A PIVKA-Ⅱ detection kit, characterized in that: It includes reagent M and reagent R, wherein the reagent M includes: diluent I and magnetic beads coupled with biotinylated mouse anti-human PIVKA-Ⅱ monoclonal antibody, and the reagent R includes diluent II and alkaline phosphatase-labeled rabbit anti-human PIVKA-Ⅱ polyclonal antibody; The structure of the magnetic beads coupled with biotinylated mouse anti-human PIVKA-Ⅱ monoclonal antibody is as follows: the surface of the magnetic beads is first coated with anti-SA antibody, then connected with SA, and then coupled with biotinylated mouse anti-human PIVKA-Ⅱ monoclonal antibody; the diameter of the magnetic beads is 0.8 μm to 3 μm; The mass ratio of the magnetic beads to the anti-SA antibody, SA, and biotinylated mouse anti-human PIVKA-Ⅱ monoclonal antibody is 0.3:0.25:0.02:0.5; The diluent I comprises: 0.03% to 0.1% Proclin 300, 0.02 to 0.05 mol / L buffer, 0.2% to 2% surfactant, 0.1% to 0.5% protein, and a pH of 7.0 to 8.0; wherein the buffer is any one of PB buffer, MOPS buffer, TES buffer, HEPES buffer and DIPSO buffer, the surfactant is any one of Brij-35, S9, Emulgen A90 and PEG-20000, and the protein is BSA or bovine gamma globulin; The diluent II comprises: 0.9% sodium chloride, 1 mM magnesium chloride hexahydrate, 0.1 mM anhydrous zinc chloride, 0.1% bovine serum albumin, 0.05% Proclin 300, and 0.02 M Tris-HCl buffer with a pH of 7.4-8.
0.
2. The PIVKA-Ⅱ detection kit according to claim 1, characterized in that: In the reagent R, the mass ratio of alkaline phosphatase to rabbit anti-human PIVKA-Ⅱ polyclonal antibody is (0.25-0.5): (0.5-1), and the mass ratio of magnetic beads to alkaline phosphatase is 0.3: (0.25-0.5).
3. The PIVKA-Ⅱ detection kit according to claim 1, characterized in that The diluent I includes 0.05% Proclin 300, 0.02 mol / L MOPS buffer, 2% PEG-20000, 0.1% bovine gamma globulin, and has a pH of 7.
4.
4. The PIVKA-Ⅱ detection kit according to claim 1, characterized in that The activity of the alkaline phosphatase is >1800 glycine U / mg protein.
5. The method for preparing the PIVKA-Ⅱ detection kit according to any one of claims 1 to 4, characterized in that: The following steps are involved: S1. Activate magnetic beads with a diameter of 0.8 μm to 3 μm with an activator, add anti-SA antibody to the activated magnetic beads for coupling reaction, then add SA for reaction, finally add biotinylated mouse anti-human PIVKA-Ⅱ monoclonal antibody for reaction, add glycine solution to quench the reaction, wash and resuspend after the reaction is completed to obtain magnetic beads coupled with biotinylated mouse anti-human PIVKA-Ⅱ monoclonal antibody, and dilute with diluent I to obtain reagent M; S2. Take alkaline phosphatase, rabbit anti-human PIVKA-Ⅱ polyclonal antibody and glutaraldehyde for cross-linking reaction. After the cross-linking reaction is completed, add ethanolamine. After the reaction is completed, dialyze to obtain alkaline phosphatase-labeled rabbit anti-human PIVKA-Ⅱ polyclonal antibody, and dilute it with diluent Ⅱ to obtain reagent R.
6. The preparation method according to claim 5, characterized in that: The method for activating the magnetic bead microparticles is specifically as follows: after repeatedly washing and resuspending the magnetic bead microparticles with PBS buffer, an activator EDC is added to react.
Citation Information
Patent Citations
Compound as well as preparation method and application thereof
CN110862438A
Exosome separation method, immunomagnetic beads and kit
CN111505264A
Enzyme scale for ELISA adsorption mensuration
CN201289484Y
Internal standard molecule for immunoprecipitation and immunoprecipitation method
WO2016136835A1
